Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study

Authors

Nancy Cross
Yukari Okubo (ORCID: https://orcid.org/0000-0002-9526-1259)
Masatoshi Abe (ORCID: https://orcid.org/0000-0002-8863-9428)
Yayoi Tada (ORCID: https://orcid.org/0000-0003-3743-135X)
Mizuho Matano (ORCID: https://orcid.org/0000-0003-4816-7021)
Keiichi Yamanaka (ORCID: https://orcid.org/0000-0003-3055-5202)
Delphine Deherder (ORCID: https://orcid.org/0000-0002-7336-1988)
Hidemi Nakagawa (ORCID: https://orcid.org/0000-0002-8272-4488)
Nicola Tilt
Hidetoshi Takahashi

Institutions

Jikei University School of Medicine (JP)
Tokyo Medical University (JP)
Mie University (JP)
Sapporo Science Center (JP)
UCB Pharma (Japan) (JP)
Takayanagi Dental Clinic (JP)
UCB Pharma (Belgium) (BE)
Teikyo University (JP)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-08-11
DOI: https://doi.org/10.1007/s13555-025-01509-9
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
UCB
Torii Pharmaceutical
Eisai
Sun Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study

Nancy Cross, Yukari Okubo, Masatoshi Abe, Yayoi Tada et al.

Aug 11, 2025

Dermatology and Therapy

Psoriasis: Treatment and Pathogenesis

article

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study

Nancy Cross, Yukari Okubo, Masatoshi Abe, Yayoi Tada, Mizuho Matano, Keiichi Yamanaka, Delphine Deherder, Hidemi Nakagawa, Nicola Tilt, Hidetoshi Takahashi

August 11, 2025article en

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(10)

Jikei University School of Medicine (JP), Tokyo Medical University (JP), Mie University (JP), Sapporo Science Center (JP), UCB Pharma (Japan) (JP), Takayanagi Dental Clinic (JP), UCB Pharma (Belgium) (BE), Teikyo University (JP)

Amgen, Bristol-Myers Squibb, UCB, Torii Pharmaceutical, Eisai, Sun Pharma

Responsible consumption and production

Openalex Percentile: Top 78%

Psoriasis: Treatment and Pathogenesis

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.